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Background: Helicobacter pylori is known to be a gastric pathogen of humans. Eradication regimens for H. pylori
infection have some side effects, compliance problems, relapses, and antibiotic resistance. Therefore, the need for
alternative therapies for H. pylori infections is of special interest. We have previously shown that polyphenols from
almond skins are active against a range of food-borne pathogens. The aim of this study was to evaluate the
antibacterial effects of natural almond skins before and after simulated human digestion and the pure flavonoid
compounds epicatechin, naringenin and protocatechuic acid against H. pylori.
Results: H. pylori strains were isolated from gastric biopsy samples following standard microbiology procedures.
Also, cagA and vacA genes were identified using PCR. Susceptibility studies on 34 strains of H. pylori, including two
reference strains (ATCC 43504, ATCC 49503), were performed by the standard agar dilution method.
Natural almond skin was the most effective compound against H. pylori (MIC range, 64 to 128 μg/ml), followed by
natural skin post gastric digestion (MIC range, 128 to 512 μg/ml), and natural almond skin post gastric plus
duodenal digestion (MIC range, 256 to 512 μg/ml). Amongst the pure flavonoid compounds, protocatechuic acid
showed the greatest activity (MIC range, 128 to 512 μg/ml) against H. pylori strains.
Conclusions: Polyphenols from almond skins were effective in vitro against H. pylori, irrespective of genotype status
and could therefore be used in combination with antibiotics as a novel strategy for antibiotic resistance.
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Helicobacter pylori is a microaerophilic Gram-negative
bacterium which colonizes the human gastric mucosa. It
is known to be a gastric pathogen of humans associated
with chronic gastritis, peptic ulcers, atrophic gastritis,
intestinal metaplasia and lymphoma or cancer develop-
ment [1,2]. Approximately 50% of the world population
is infected with H. pylori, with prevalence rates ranging
from 20% to more than 80% in certain countries [3]. H.
pylori has been identified as group 1 carcinogen by the* Correspondence: gmandalari@unime.it
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reproduction in any medium, provided the orInternational Agency for Research on Cancer [4]. The
observation that only a subset of infected individuals de-
velops severe gastroduodenal diseases may depend on
the virulence of the infecting organism. Amongst the
different genetic determinants involved in H. pylori vi-
rulence are the cytotoxin-associated gene (cagA) and
the vacuolating cytotoxin gene (vacA). VacA, which is
present in all H. pylori strains, contains at least two vari-
able parts relevant to virulence [5]. The s region encod-
ing the signal peptide exists as s1 or s2 allelic types, and
the m region (middle) occurs as m1 and m2 allelic types
[6]. CagA, which is not present in every H. pylori strain
[7], is a marker for a pathogenicity island (PAI) [8] asso-
ciated with more severe clinical outcomes [9]. It has also
been demonstrated that CagA is required to disrupt the
organization of apical junctions and perturb epithelialral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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level of cytotoxin activity than other genotypes. A strong
association between cagA and vacA signal sequence type
s1 has been reported [5]. Strains carrying s1 m1 mosaic
combination secrete vacuolating cytotoxin in contrast to
those with s2 m2 activity [11].
The standard treatment for H. pylori related disease is
a combination of antimicrobial agents and anti-acid
agents [12]. However, side effects for these regimes are
common and a major concern is the development of
antimicrobial resistance [13]. As a result, several natur-
ally occurring substances have been investigated as
potential alternatives for the treatment of H. pylori in-
fection [14-18].
Almonds (Prunus dulcis D.A. Webb) are a rich source
of nutrients and phytochemicals such as vitamin E, mo-
nounsatured fatty acids and polyunsatured fatty acids [19].
Other health promoting compounds mainly present in al-
mond skins are polyphenols which have been shown to be
bioaccessible during simulated digestion in the gut [20,21].
Among polyphenols, flavonoids are secondary metabolites
well documented for their biological effects, including an-
ticancer, antiviral, antimutagenic, anti-inflammatory and
antimicrobial activities [22-24]. We have previously dem-
onstrated that polyphenols from almond skins are active
against Gram-positive bacteria including Staphylococcus
aureus and Listeria monocytogenes and the Gram-negative
Salmonella enterica [25]. Natural almond skins also in-
duced a significant decrease in Herpes simplex virus type
2 replication [26]. The antioxidant and anti-inflammatory
potential of almond skin polyphenols has also been dem-
onstrated using an experimental model of inflammatory
bowel disease [27].
The aim of the present study was to investigate the
antimicrobial properties of natural almond skins before
and after simulated human digestion in the upper GI
tract and the pure flavonoid compounds epicatechin,
naringenin and protocatechuic acid against H. pylori
strains isolated from gastric biopsies of subjects attend-
ing an outpatient clinic in Southern Italy. Their clinical
relevance has also been elucidated.
Methods
Almond skins
Natural almond skins (NS) were prepared from Californian
almonds by treatment with liquid nitrogen as previously
reported [20].
In vitro digestion studies
The protocol used to simulate digestion of natural almond
skins under gastric and duodenal conditions in vitro has
been previously described [21].
Briefly, for the gastric digestion, 1.5 g of NS was
suspended in 12.4 mL acidic saline (150 mM NaCl,pH 2.5) and readjusted to pH 2.5 with HCl. Phosphat-
idylcholine (Lipid Products, UK) vesicle suspension, pep-
sin (Sigma, UK) and gastric lipase analogue (Amano
Enzyme, Japan) were added so that the final concentra-
tions were 2.4 mmol/L, 146 U/mL and 60 U/mL, re-
spectively. Gastric digestion was performed in a shaking
incubator (170 rpm, 37°C) for 2 h.
For the simulated gastric plus duodenal digestion,
the pH was raised to 6.5 by addition of NaOH and
the following enzymes were added: α-chymotrypsin
(Sigma, 5.9 U/mL), trypsin (Sigma, 104 U/mL),
colipase (Sigma, 3.2 μg/mL), pancreatic lipase (Sigma,
54 U/mL), and α-amylase (Sigma, 25 U/mL) in the
presence of sodium taurocholate (4 mmol/L) and
sodium glycodeoxycholate (4 mmol/L). Gastric plus
duodenal digestion was performed in a shaking incu-
bator (170 rpm, 37°C) for 1 h.
Almond skin extracts
Polyphenol-rich extracts from NS, NS post in vitro gastric
digestion (NS G) and NS post in vitro gastric plus duo-
denal digestion (NS G +D) were prepared as previously
described and their composition has been previously
reported [21].
Patients, H. pylori strains and culture conditions
Two reference American Type Culture Collection strains
of H. pylori (ATCC 43504 and ATCC 49503) and thirty
two clinical isolates recovered from gastric biopsy sam-
ples of dyspeptic adults (23 women, 9 men; average age,
51 years) undergoing digestive endoscopy at the Endos-
copy Unit of the Department of Internal Medicine of the
University of Messina, Messina, Italy, were used in this
study. None of the patients had previously undergone
eradication therapy. All study subjects gave their in-
formed consent and the study was approved by the local
ethical committee (Comitato Etico Scientifico A.O.U.
Policlinico “G. Martino” Messina, Italy). Diagnosis of
peptic ulcer (PU) and non-ulcer dyspepsia (NUD) or
gastritis was based on endoscopic examination of the
stomach and duodenum. Biopsy samples were taken for
each patient for culture. Isolates were derived from pa-
tients suffering from gastritis (n = 27; 84.37%), or NUD
(n = 5; 15.62%).
Gastric biopsy specimens for culture were placed in
the sterile screw-capped tubes containing 0.5 ml sterile
saline and transported to the microbiology laboratory
within 2 h. The samples were soaked and sowed in se-
lective (Pylori agar, BioMérieux) and non-selective
(Columbia agar with 7% horse blood, CB, Oxoid) culture
media. Cultures were incubated for 7 days at 37°C under
microaerophilic conditions. Grown bacteria were identi-
fied as H. pylori by typical morphology, Gram staining
results and positive reactions to oxidase, catalase, and
Table 1 Primers used for cytotoxin-associated gene (cagA) and vacuolating cytotoxin gene (vacA) typing of H. pylori
Gene target Primer designation Nucleotide sequence Amplicon size (bp)
vacAS-F VacAS-F 5’-ATGGAAATACAACAAACACAC-3’ 259 (type s1)
VacAS-R 5’-CTGCTTGAATGCGCCAAAC-3’ 286 (type s2)
vacA midregion VacAM-F 5’-CAATCTGTCCAATCAAGCGAG-3’ 567 (type m1)
VacAM-R 5’-GCGTCAAAATAATTCCAAGG-3’ 642 (type m2)
cagA CagA-F 5’-GATAACAGGCAAGCTTTTGAGAGGGA-3’ 393
CagA-R 5’-CCATGAATTTTTGATCCGTTCGG-3’
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lence factors have been determined in all strains by PCR
method.
All strains were harvested by suspension in Brucella
broth (Difco) supplemented with 10% fetal bovine serum
(BB, Euroclone) and 30% glycerol and stored in liquid
nitrogen until used.DNA extraction from H. pylori isolates
DNA was extracted from H. pylori isolates using the
QIAamp DNA Mini Kit (Qiagen, Milan, Italy) according
to the manufacturer’s instructions. Briefly, one colony was
harvested from an agar plate and added to an appropriate
volume of phosphate-buffered saline homogenized by
vortexing. Twenty microliters of a proteinase K solution
(20 mg/mL) and 200 μL of buffer AL provided in the kit
were then added, followed by incubation at 56°C for
10 min. Next, 200 μL of ethanol (96%) were added. The
mixture was then loaded onto the QIAamp spin column
provided in the kit and centrifuged at 6000 g for 1 min.
The QIAamp spin column was placed in a 2-mL collec-
tion microtube, and the tube containing the mixture was
discarded. The column material was washed (500 μL each)
with the first washing buffer (buffer AW1) and with the
second washing buffer (buffer AW2) provided in the kit.
Finally, the DNA was eluted with 150 μL of a third buffer
(buffer AE) provided in the kit.Oligonucleotide primers
The primers targeting the vacA gene (region m and re-
gion s) and cagA genes [28] used in the PCR assay for
the analysis of H. pylori isolates, are reported in Table 1.
The primers were synthesised by MWG-Biotech AG
(Mannheim, Germany).Table 2 Prevalence of cagA and allelic variants of vacA on the
Gastroduodenal condition CagA
CagA + CagA -
Gastritis * 15 (55.5%) 12 (44.5%)
NUD ** 0 (0%) 5 (100%)
*Strains isolated from patients with gastritis (n = 27) **Strains isolated from patientsPCR conditions
The amplification was performed using a PCR Sprint-
Thermal Cycler (Hybaid, Ashford, UK) and carried out
in 50 μL reaction volume containing 200 μmol/L (each)
dNTP, 0.1 μmol/L (each) primer, 1X PCR buffer,
50 mmol/L KCl, 10 mmol/LTris–HCl pH 8.8, 0.1% Triton
X-100, 50 mmol/L MgCl2, 2 U of Taq DNA polymerase
and 5 μL of template DNA or water for the negative con-
trol. The temperature profile for the PCR was as follows:
an initial step of 4 min at 95°C, followed by a denaturation
step for 1 min at 95°C, an annealing step for 1 min at
52°C (for vacA PCR) or 59°C (for cagA PCR), and a primer
extension step for 1 min at 72°C. After the 35th cycle, the
extension step was prolonged for 10 min in order to
complete synthesis of all strands after which the samples
were kept at 4°C until analysis. A negative control lacking
of the DNA template was included in each experiment.
The H. pylori strains used as positive controls in the PCR
tests included H. pylori ATCC 43504 and H. pylori ATCC
49503. Detection of PCR products was performed by gel
electrophoresis. Samples (5 μL) of final PCR products
were loaded onto 1.5% agarose gel and subjected to elec-
trophoresis in 1X TAE (0.04 mol/L Tris–acetate,
0.001 mol/L EDTA) buffer for 60–90 min at 100 V. The
gels were stained with ethidium bromide and photo-
graphed under UV light trans-illumination. A 100-bp
DNA ladder (BioLab New England, Celbio, Milan, Italy)
was included on each gel as a molecular size standard.
Susceptibility testing
The minimum inhibitory concentration (MIC) was
assayed by the standard agar dilution method according
to the guidelines of the Clinical and Laboratory Stan-
dards Institute (CLSI) [29] using CB. Twofold serial dilu-
tions of the compound tested ranging from 0.016 μg/mL
to 1.024 μg/mL were used. Frozen stock cultures wereH. pylori strains
VacA
s1 s2 m1 m2
21 (77.8%) 6 (22.2%) 17 (63%) 10 (37%)
3 (60%) 2 (40%) 2 (40%) 3 (60%)
with non-ulcer dyspepsia (n = 5).
Table 3 Prevalence of cagA related to the main allelic combinations of vacA
Gastroduodenal condition CagA+ CagA-
s1m1 s1m2 s2m2 s1m1 s1m2 s2m1 s2m2
Gastritis* 8(53.3%) 5(33.3%) 2(13.4%) 6(50%) 2(16.7%) 3(25%) 1(8.3%)
NUD** 0(0%) 0(0%) 0(0%) 1(20%) 2(40%) 1(20%) 1(20%)
*Strains isolated from patients with gastritis (n = 27) **Strains isolated from patients with non-ulcer dyspepsia (n = 5).
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under microaerophilic conditions. Bacterial growth was
taken from the plates, resuspended in BB and grown
under shaking (125 rpm) at 37°C for 24 h. H. pylori cul-
tures in the exponential phase of growth were diluted
with BB to contain about 5 × 107 CFU/mL by adjusting
the turbidity of the suspension to match the MacFarland
no. 1 standard. Ten-microliter aliquots of the suspension
were inoculated on CB containing twofold serial dilu-
tions of the compound tested. Compound-free CB media
were included in each experiment to confirm the viabil-
ity of the inoculum and to observe the growth of any
contaminants. CB incorporating twofold serial dilutions
of the solvent dimethil sulfoxide was included as a
growth control to ensure that the viability of the H.
pylori strains was not affected by the dimethil sulfoxide
used to dissolve the compound. All plates were incubated
at 37°C in a microaerophilic atmosphere and examined
after 3 days. For quality control, H. pylori ATCC strains
43504 and 49503 were tested in each run. Amoxicillin
(Sigma Aldrich S.r.l., Italy), and clarithromycin (Abbott S.
p.A., Italy), were used as control compounds for compara-
tive analyses. According to CLSI breakpoints, the resist-
ance breakpoints were 0.5 μg/mL for amoxicillin and
1 μg/mL for clarithromycin [29]. The MIC was considered
the lowest concentration at which the compound inhi-
bited the development of visible bacterial growth on the
agar plates. All MIC determinations were performed in
duplicate for each strain.
Results
To type the H. pylori strains isolated from the patients
examined in this study, we amplified by PCR different
alleles of the genes of the two major virulence factors ofTable 4 Minimum inhibitory concentration of almond
skin extracts against H. pylori (ATCC strains and clinical
isolates)
MIC range MIC 50 MIC 90
NS 64-128 64 128
NS G 128-512 128 256
NS G + D 256-512 256 512
Values are expressed as μg ml-1.
NS: Natural almond skin polyphenol-rich extract.
NS G: Natural almond skin polyphenol-rich extract post gastric digestion.
NS G + D: Natural almond skin polyphenol-rich extract post gastric plus
duodenal digestion.this bacteria, cagA and vacA. The amplification results
are shown in Table 2. Fifteen out of 32H. pylori isolates
were cagA positive, representing 55.5% (15/27) of the
isolates recovered from patients with gastritis. No strain
identified from patients with NUD was cagA positive.
The prevalence of the allelic variants of s1 and m1 of
vacA was higher in the strains isolated from patients
with gastritis compared with the strains isolated from
NUD patients (77.8% versus 60%, and 63% vs 40%, re-
spectively). When the cagA and vacA genotypes were
combined and analyzed in relation to the clinical out-
come (Table 3), the cagA + strains with the allelic variant
s1m1 of vacA were only present in the strains isolated
from gastritis patients (53.3%).
The MIC values of natural almond skin (NS), NS post
in vitro gastric digestion (NS G) and NS post in vitro
gastric plus duodenal digestion (NS G +D) against 34
H. pylori strains including 2 ATCC H. pylori strains are
shown in Table 4. Results of negative controls containing
DMSO (maximum 1% v/v) indicated the complete ab-
sence of inhibition of all the H. pylori strains tested (data
not shown). All extracts inhibited the growth of both the
clinical isolates and the reference strains. As expected, NS
was the most effective (MIC range, 64 to 128 μg/mL),
followed by NS G (MIC range, 128 to 512 μg/mL) and NS
G +D (MIC range, 256 to 512 μg/mL). MIC values of 64,
128 and 256 μg/mL NS, NS G and NS G +D, respectively,
inhibited the growth of 50% of the H. pylori tested strains.
These results clearly confirm that all three polyphenol-
rich extracts acted as good growth inhibitors against H.
pylori with different virulence irrespective of the cagA and
vacA status. In other words, there was no difference in the
suppression of growth between the 8H. pylori clinical iso-
lates harboring the cagA+/vacAs1/m1 genotype, including
the quality control strains (ATCC 43504 and 49503), and
the other H. pylori genotypes.Table 5 Minimum inhibitory concentration of almond
skin flavonoids against H.pylori (ATCC strains and
clinical isolates)
MIC range MIC 50 MIC 90
Epicatechin 128-1024 512 1024
Naringenin 128-1024 256 512
Protocatechuic acid 128-512 128 256
Values are expressed as μg ml-1.
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protocatechuic acid against H. pylori strains are reported
in Table 5. Protocatechuic acid showed the greatest activity
with MIC values of 128 μg/mL and 256 μg/mL against
50% and 90% of the tested strains, respectively. Epicatechin
was the least effective compound against H. pylori (MIC of
512 μg/mL against 50% of the H. pylori strains).
All H. pylori strains tested were susceptible to amoxicillin
(MIC90 0.25 μg/mL; range between 0.016 – 0.25 μg/mL).
The MIC90 value of clarithromycin against H. pylori iso-
lates was 0.5 μg/mL with MIC values ranging between
0.016 and 4 μg/mL. Two (6%) out of 32 isolates tested
were clarithromycin resistant, one of which was isolated
from patients suffering from gastritis harbouring the
cagA+/vacAs1/m1 genotype.
The two clarithromycin-resistant strains were in-
hibited by almond skin extracts (NS, NS G, NS G +D) at
128 μg/mL; the MIC values of pure compounds (epicate-
chin, naringenin, protocatechuic acid) against these two
strains were 256, 256, and 128 μg/mL, respectively.
Quality control MICs were within acceptable limits for
all antimicrobial susceptibility testing.
Discussion
The results reported in the present paper demonstrated
that polyphenols present in almond skins are effective
against H. pylori strains, both ATCC and clinical isolates.
As previously reported [21,26], NS was the most active
against the tested strains. This result could be due to the
highest polyphenols concentration in NS, whereas a de-
crease in the total phenolic content was observed post
in vitro gastric and post in vitro gastric plus duodenal
digestion [21]. Catechin, epicatechin, kaempferol (agly-
cone and conjugated) and isorhamnetin (aglycone and
conjugated) were the major compounds identified in NS
[21], leading to assume the combination of these poly-
phenols was responsible for the higher activity against
H. pylori. Quercetin and kaempferol were shown to be
active against a CagA + and a CagA- strain of H. pylori
and a relationship between antimicrobial potential and
antioxidant activity was only reported for the CagA- G
21 strain [18]. The same authors have also recently
reported an increased susceptibility to resveratrol of H.
pylori strains isolated from patients suffering from gas-
tric carcinomas [30]. The investigation of the isolated
compounds in the present work demonstrated that
protocatechuic acid was more active than naringenin
and epicatechin and the effectiveness of protocathechic
acid against H. pylori in broth and stomach homogenates
from mice has also been demonstrated by Liu et al. [31],
with no differences between antibiotic susceptible and re-
sistant strains. Other investigations have reported promis-
ing effect of natural compounds, such as hydrolysable
tannins and lignans, on the proliferation of H. pylori andthe prevention of gastric carcinogenesis [32,33]. Reports
on the mechanism of action of a range of flavonoids have
shown that isoflavones and chalcones inhibited the urease
secreted by H. pylori to survive the acidic conditions
found in the stomach [34,35]. Other flavonoids may also
be responsible for the neutralization of the vacA via inter-
ference of the toll-like receptor 4 signaling induced by H.
pylori [36,37]. A recent study reported that the antimicro-
bial potential of the oligopeptide C12K-2 against H. pylori
has a dual mode of action on both membrane and cyto-
plasmatic components [38]. Although the rate of resist-
ance to clarithromycin has significantly increased in
several countries (13), the observed resistance to this anti-
biotic in the H. pylori isolates tested in the present work
was surprisingly low (6%).
Conclusions
In conclusion, we have shown that polyphenols from
almond skins were effective in vitro against H. pylori,
irrespective of the bacterial genotype which is indepen-
dent of the presence of the cagA, and could therefore be
used in combination with antibiotics as a novel strategy
for antibiotic resistance.
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